





3rd International Symposium on Functional Renal Imaging, 17th October 2019

Histopathology of AKI

Peter Boor pboor@ukaachen.de

Pathology & Nephrology RWTH Aachen, Germany


















Classification of acute kidney injury (AKI)




AKI is common particularly on intensive wards

retrospective analyses (USA, 7 intensive wards, n=5.383) maximal reached RIFLE-stage






Causes of acute kidney injury (AKI)



AKI in renal biopsies



Biopsied

3. Small-vessel disease

Thrombotic microangiopathy Renal atheroembolism Small-vessel vasculitis

Biopsied

4. Glomerular disease

Anti-GBM disease

Lupus nephritis

Postinfectious glomerulonephritis

Infective endocarditis

Membranoproliferative glomerulonephritis

Cryoglobulinemia

IgA nephropathy/Henoch-Schönlein purpura

5. Acute tubular necrosis

Ischemia

Nephrotoxins

Rhabdomyolysis

Radiocontrast agents

45%

Not-biopsied

6. Acute interstitial nephritis

Drugs

Biopsied


Infection


Systemic disease

Biopsied


Modified from Floege/Feehally, Comprehensive clinical nephrology


Case 1: Clinical presentation: unclear AKI, Voltaren medication (NSAID), contact with murine feces







Case 2: Living donor transplant 1 week ago. Crea increase from 2,1 to 3 in 2 days. Rejection?







Case 3: Time 0 biopsy, deceased donor











Case 4: Transplant biopsy after reperfusion (no other data provided)























Ischemia-reperfusion injury in mice (warm, 35 min, females, time-point 6 hrs)



Ischemia-reperfusion injury in mice (warm, 35 min, females, time-point 24 hrs)




Etiology of acute kidney injury (AKI)



Modified from Harrison's Principles of internal medecine, 20th edition

Conventional animal models for AKI



Glomerular:

- a)Puromycin aminoglycoside (PAN) model
- b) Adriamycin induced AKI (FSGS)
- c) Nephrotoxic nephritis (NTN)

Vascular:

- STX2 Model
- **Anti-GBM Model**


Tubular- Endogenous toxins:

- a) Pigmentnephropathy
- Glycerol model (rhabdomylosis)
- Infusion of myoglobin
- b) Warfarin-nephropathy
- c) Sepsis induced AKI (also prerenal)
- LPS Modell
- Cecal ligation and punction (CLPmodel)

Tubular-Exogenous toxins:


- a) Cisplatin induced AKI
- b) Folic acid induced AKI
- c) Aristolochic acid induced AKI
- d) Adriamycin induced AKI
- e) Contrast induced AKI
- f) Organic mercury induced AKI

Clinical phases of AKI



Days After Insult

Clinical phases of AKI



Common problems of models for AKI

different

biology


same

environment

young age,

responsive

vasculature




Challenges and solutions in translation

Preclinical stage Challenges Solutions Experimental models do not adequately Use of animal models with multiple represent human phenotype comorbidities, treated with common medications Lack of comorbidities Improved randomization/blinding Lack of medication use protocols for animal work Experimental protocol Longer-term outcomes in animal Inter-species variability experiments Collateral circulation Use of human ex vivo tissue · Ischemia tolerance Translation into human clinical Publication/submission bias trials Early translation: Phase I/II trials Challenges Solutions Trials often single centre, small Translation to scale, short duration Large-scale clinical trials Lack power to detect: Multi-centre randomized clinical trials Impact of underlying comorbidities Powered for long-term 'hard' end · 'Hard' end points: e.g. death/ points hospital admissions Late translation: Phase III trials and wider adoption Challenges Solutions Integrated research networks Funding supported by Government/charity Lack of medicinal product or to provide funding and research patentable device leads to governance lack of industry sponsorship Dissemination and diffusion of results through publication, · Lack of widespread adoption protocol development and of technique

adoption by international clinical guideline committees

Combine clinical & preclinical research - Role of MIF in AKI


Cohort studies in patients after cardiac surgery



Combine approaches - role of MIF in AKI & tubular injury


Clinical studies

patients after cardiac surgery




Preclinical studies

Different animal AKI models & interventions & in vitro mechanistic studies



Combine approaches - role of MIF in AKI & tubular injury




Other processes in AKI – microvascular dysfunction (in vivo imaging)

Kidney autofluorescence (tubular cells)


Peritubular capillaries (2000 kDa dextrane-FITC, 50 µl of 5mg/ml)

Evans blue (1µl/g BW of 1mg/ml)






Approach to molecular imaging in kidneys (renal fibrosis)




Sun...Boor, Sci Transl Med 2019

Elastin is up-regulated in models of renal fibrosis (target validation)



Confirmation in other animal models




Rat: UUO, 5/6 Nx, chronic anti-Thy1.1 Nephritis, adenine nephropathy


Mouse: UUO, I/R injury, NTN, Alport mice (Col4a3-/-), 5/6 Nx, Folic acid nephropathy

Methods: IHC, IF, WB, qRT-PCR, electron microscopy

Elastin is up-regulated in patients with renal fibrosis




Elastin expression in human kidneys




<u>Elastin-specific magnetic resonance contrast agent (ESMA)</u>


¹⁵³Gd-DTPA linked to D-amino acid D-phenylalanine



ESMA MRI in adenine nephropathy



ESMA MRI in adenine nephropathy




Specificity


Elastin expression


Renal Gd-content

ex vivo competition


in vivo competition









(laser ablation) inductively coupled plasma mass spectrometry – LA-ICP-MS




ESMA binds to human kidney ex vivo




Renal Fibrosis





ESMA pharmacokinetics & longitudinal measures






ESMA imaging monitors anti-fibrotic therapy efficacy







Imatinib in I/R




ESMA imaging - just another surrogate for GFR?




ESMA imaging in reversible adenine nephropathy




Elastin imaging identifies residual renal fibrosis not detectable using routine kidney function measurement




Collagen imaging in renal fibrosis






Collagen imaging in renal fibrosis




Baues...Boor, Kidney Int 2019




Yes – perhaps more than ever...


Digital & Computational Pathology



Digital Pathology – augmented by deep learning



Digital Pathology – augmented by deep learning



Conclusions

Acute Kidney Injury

- common & relevant disease
- pathophysiology mainly from animal models (relevance?)
- limited data from human kidney tissue
- hallmark tubular injury (variable degree)
- various other processes involved (microvascular dysfunction...)
- non-invasive & disease process-specific biomarkers needed

pboor@ukaachen.de





